Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-01
2008-10-21
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S259100, C514S262100, C514S265100, C514S300000, C514S303000, C544S253000, C544S255000, C544S262000, C546S113000, C546S114000, C546S115000, C546S118000
Reexamination Certificate
active
07439246
ABSTRACT:
In general, the instant invention comprises compounds of Formulas I and IIincluding pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
REFERENCES:
patent: 3646202 (1972-02-01), Mrozik
patent: 4602912 (1986-07-01), de Sousa et al.
patent: 4663341 (1987-05-01), Jacobson
patent: 4753940 (1988-06-01), Sturm et al.
patent: 4845093 (1989-07-01), Haga et al.
patent: 4908056 (1990-03-01), Tseng
patent: 5132314 (1992-07-01), Maienfisch et al.
patent: 5135949 (1992-08-01), von der Saal et al.
patent: 5646176 (1997-07-01), Golik et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6022884 (2000-02-01), Mantlo et al.
patent: 6143743 (2000-11-01), Wilde et al.
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6214344 (2001-04-01), Schwall et al.
patent: 6232320 (2001-05-01), Stewart et al.
patent: 6262094 (2001-07-01), Hoefle et al.
patent: 6355660 (2002-03-01), Ricks et al.
patent: 6380386 (2002-04-01), Seitz et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6521622 (2003-02-01), Ricks et al.
patent: 6559341 (2003-05-01), Tohnishi et al.
patent: 6603044 (2003-08-01), Tohnishi et al.
patent: 6620827 (2003-09-01), De la Brouse-Elwood et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6696487 (2004-02-01), Gerusz et al.
patent: 6706740 (2004-03-01), Ricks et al.
patent: 6750246 (2004-06-01), Kadow et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6900208 (2005-05-01), Salvati et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 6962915 (2005-11-01), Das et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 7030112 (2006-04-01), Salvati et al.
patent: 2001/0041673 (2001-11-01), Fossa
patent: 2003/0082631 (2003-05-01), Gustavsson et al.
patent: 2003/0232765 (2003-12-01), Carter et al.
patent: 2003/0232831 (2003-12-01), Dyckman et al.
patent: 2004/0044203 (2004-03-01), Wittman et al.
patent: 2004/0048891 (2004-03-01), Kato et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0072832 (2004-04-01), Bhide et al.
patent: 2004/0082582 (2004-04-01), Dyckman et al.
patent: 2004/0209886 (2004-10-01), Salvati et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 2004/0242603 (2004-12-01), Fujiwara et al.
patent: 2005/0004143 (2005-01-01), Dugar et al.
patent: 2005/0038035 (2005-02-01), Takasugi et al.
patent: 2005/0043306 (2005-02-01), Leftheris et al.
patent: 2005/0143398 (2005-06-01), Das et al.
patent: 2005/0239820 (2005-10-01), Borzilleri et al.
patent: 2005/0245530 (2005-11-01), Borzilleri et al.
patent: 2005/0288289 (2005-12-01), Crispino et al.
patent: 2006/0004006 (2006-01-01), Borzilleri et al.
patent: 200195986 (2002-04-01), None
patent: 31 39 457 (1983-04-01), None
patent: 197 10 609 (1998-09-01), None
patent: 0 151 962 (1985-08-01), None
patent: 0 119 774 (1987-06-01), None
patent: 0 152 910 (1989-07-01), None
patent: 0 919 542 (1999-06-01), None
patent: 1 243 582 (2002-09-01), None
patent: 1 411 046 (2004-04-01), None
patent: 1 415 987 (2004-05-01), None
patent: 2 106 500 (1983-04-01), None
patent: 54-115384 (1979-09-01), None
patent: 57-51835 (1982-03-01), None
patent: 62-62 (1987-01-01), None
patent: 62-5959 (1987-01-01), None
patent: 62-5960 (1987-01-01), None
patent: 62-135463 (1987-06-01), None
patent: 2003-321472 (2003-11-01), None
patent: 1761753 (1992-09-01), None
patent: WO 97/16452 (1997-05-01), None
patent: WO 97/17329 (1997-05-01), None
patent: WO 98/41513 (1998-09-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/02514 (1999-01-01), None
patent: WO 99/24404 (1999-05-01), None
patent: WO 00/43366 (2000-07-01), None
patent: WO 00/50405 (2000-08-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 00/75145 (2000-12-01), None
patent: WO 01/09134 (2001-02-01), None
patent: WO 01/21576 (2001-03-01), None
patent: WO 01/21596 (2001-03-01), None
patent: WO 01/42243 (2001-06-01), None
patent: WO 01/47890 (2001-07-01), None
patent: WO 01/94353 (2001-12-01), None
patent: WO 02/32872 (2002-04-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 02/44156 (2002-06-01), None
patent: WO 02/051397 (2002-07-01), None
patent: WO 02/085859 (2002-10-01), None
patent: WO 03/000194 (2003-01-01), None
patent: WO 03/000660 (2003-01-01), None
patent: WO 03/011028 (2003-02-01), None
patent: WO 03/033472 (2003-04-01), None
patent: WO 03/042172 (2003-05-01), None
patent: WO 03/082208 (2003-10-01), None
patent: WO 03/091229 (2003-11-01), None
patent: WO 03/099286 (2003-12-01), None
patent: WO 04/001059 (2003-12-01), None
patent: WO 2004/002410 (2004-01-01), None
patent: WO 2004/032846 (2004-04-01), None
patent: WO 2004/048386 (2004-06-01), None
patent: WO 2004/054514 (2004-07-01), None
patent: WO 2004/058144 (2004-07-01), None
patent: WO 2004/060305 (2004-07-01), None
patent: WO 2005/005389 (2005-01-01), None
patent: WO 2005/021554 (2005-03-01), None
patent: WO 2005/026124 (2005-03-01), None
patent: WO 2005/030140 (2005-04-01), None
patent: WO 2005/042537 (2005-05-01), None
patent: WO 2005/058891 (2005-06-01), None
patent: WO 2005/082854 (2005-09-01), None
patent: WO 2005/082855 (2005-09-01), None
patent: WO 2005/097790 (2005-10-01), None
patent: WO 2005/121125 (2005-12-01), None
patent: WO2006/104161 (2006-10-01), None
“Hepatocyte growth factor/scatter factor, Met and cancer references”, Van Andel Institute, http://www.vai.org/vari/metandcancer/ (as revised Oct. 4, 2005).
U.S. Appl. No. 11/406,795, filed Apr. 19, 2006, Borzilleri et al.
Kitamura, C. et al., “Synthesis and reactions of 3,3′-dibromodihydrodipyrrins”, J. Chem. Soc. Perkin Trans. 1, pp. 1443-1447 (1997).
Koch, V. et al., “Chemistry of 3-Hydroxypyridine Part 2: Synthesis of 5,6-Dihalo-3-hydroxypyridines”, Synthesis, pp. 499-501 (1990).
Lai, J.-F. et al., “Involvement of Focal Adhesion Kinase in Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells”, The Journal of Biological Chemistry, vol. 275, No. 11, pp. 7474-7480 (2000).
Lee, J.-H. et al., “A novel germ line juxtamembraneMetmutation in human gastric cancer”, Oncogene, vol. 19, pp. 4947-4953 (2000).
Lubensky, I.A. et al., “Hereditary and Sporadic Papillary Renal Carcinomas with c-metMutations Share a Distinct Morphological Phenotype”, American Journal of Pathology, vol. 155, No. 2, pp. 517-526 (1999).
Masuya, D. et al., “The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients”, British Journal of Cancer, vol. 90, pp. 1555-1562 (2004).
Matsumoto, K. et al., “Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions”, Critical Reviews in Oncogenesis, vol. 3, Nos. 1,2, pp. 27-54 (1992).
Montesano, R. et al., “Indentification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor”, Cell, vol. 67, pp. 901-908 (1991).
Morrill, C. et al., “Synthesis of Functionalized Vinyl Boronates via Ruthenium-Catalyzed Olefin Cross-Metathesis and Subsequent Conversion to Vinyl Halides”, J. Org. Chem., vol. 68, No. 16, pp. 6031-6034 (2003).
Park, M. et al., “Sequence ofMETprotooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors”, Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6379-6383 (1987).
Quintela, J.M. et al., “A Ready One-pot Preparation for Pyrrolo[2,1-f][1,2,4]triazine and Pyrazolo[5,1-c]pyrimido[4,5-e][1,2,4]triazine Derviatives”, Tetrahedron, vol. 52, No. 8, pp. 3037-3048 (1996).
Rong, S. et al., “Met Expression and Sarcoma Tumorigenicity”, Cancer Research, vol. 53, pp. 5355-5360 (1993).
Rong, S. et al., “Met Proto-oncogent Product is Overexpressed in Tumors of p53-deficient Mice and Tumo
Borzilleri Robert M.
Cai Zhen-wei
Chen Xiao-Tao
Chen Zhong
Huynh Tram N.
Bristol--Myers Squibb Company
Davis Zinna N
Gibbons Maureen S.
Greenblatt Gary D.
LandOfFree
Fused heterocyclic kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012031